上皮性卵巢癌组织中FoxM1的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2023.04.005

Abstract

Abstract: OBJECTIVE： To investigate expression of forkhead box protein M1 (FoxM1) in epithelial ovarian cancers and to determine its association with clinicopathological characteristics，and with epithelial mesenchymal transition (EMT)-related factors，E-cadherin and vimentin. METHODS： Expressions of FoxM1，E-cadherin and vimentin in 41 cases of epithelial ovarian cancer，17 cases of borderline ovarian tumors and 20 cases of normal ovarian tissues were detected by immunohistochemistry. χ² test was used to compare differences in the expression of FoxM1 between epithelial ovarian cancer tissues，borderline ovarian tumors and normal ovarian tissues. In addition，correlations were investigated among expressions of FoxM1，E-cadherin and vimentin，and clinicopathological characteristics of epithelial ovarian cancer patients. RESULTS： The positive expression rates of FoxM1，E-cadherin and vimentin in ovarian cancer tissues were 95.12%，82.93% and 70.73% respectively，and the high expression rates were 51.22%，53.66% and 46.34% respectively. The positive expression and high expression rates of FoxM1 in ovarian cancer tissues were significantly higher than those in the borderline ovarian cancer tissues and normal ovarian tissues (P<0.05). The expressions of FoxM1，E-cadherin and vimentin in ovarian cancer tissues were related to the clinical stages and lymph node metastasis of patients. The high expression rates of FoxM1 and vimentin in ovarian cancer tissues of patients with clinical stage III-IV and lymph node metastasis were significantly higher than those of patients with stage I-II and with no lymph node metastasis，respectively. The high expression rates of E-cadherin were significantly lower than those of patients with stage I-II and no lymph node metastasis (P<0.05). Spearman analysis showed that there were significant and positive correlations between FoxM1 and vimentin expression levels in epithelial ovarian cancer tissues(φ=0.562，P<0.05)，but there were significant and negative correlations between them and E-cadherin expression levels (φ=-0.440，-0.366，P<0.05). CONCLUSION： Expression of FoxM1 was significantly up regulated in epithelial ovarian cancers，and was related to clinical stages and lymph node metastasis. FoxM1 may therefore promote the occurrence，progression and metastasis of epithelial ovarian cancer via the EMT process.

Key words: epithelial ovarian cancer, fork head box transcription factor M1, epithelial mesenchymal transformation, E-cadherin, vimentin, pathological characteristics

CLC Number:

R737.31

QIN Xiyuan, ZHU Ying, LI Weitao, ZHENG Xiaoling, LIANG Yuanqiu. Expression and clinical significance of FoxM1 in epithelial ovarian cancers[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 273-278.

References

[1] 崔粮驿, 孙天水, 毕芳芳, 等. 626例上皮性卵巢癌的预后分析[J]. 中国妇产科临床杂志, 2019, 20(6): 487-490.
[2] MENG X, XU Y R, NING X H. Tumor microenvironment acidity modulates ROR1 to promote epithelial-mesenchymal transition and hepatocarcinoma metastasis[J]. J Cell Sci, 2021, 134(7): jcs255349.
[3] GU L, LIU H M. Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy[J]. World J Pediatr, 2020, 16(2): 113-119.
[4] 葛思辰, 蒋成义. miR-34a通过靶向FOXM1对鼻咽癌细胞增殖和上皮间质转化的影响[J]. 中华全科医学, 2021, 19(12): 2012-2015.
[5] 蒋宗胜. 基于转录因子FOXM1调控下的抗非小细胞肺癌上皮间质转化的机制研究[D]. 福州: 福建医科大学, 2018.
[6] HAFEZ A M, HARB O A, ETMAN W M, et al. Forkhead box M1 over-expression and dachshund homolog 1 down-regulation as novel biomarkers for progression of endometrial carcinoma in Egyptian patients[J]. Contemp Oncol, 2021, 25(2): 107-117.
[7] ZHANG H M, ZHONG H, LI L, et al. Overexpressed transcription factor FOXM1 contributes to the progression of colorectal cancer[J]. Mol Med Rep, 2016, 13(3): 2696-2700.
[8] CHENG Y, ZHOU Y, JIANG W J, et al. Significance of E-cadherin, β-catenin, and vimentin expression as postoperative prognosis indicators in cervical squamous cell carcinoma[J]. Hum Pathol, 2012, 43(8): 1213-1220.
[9] ZHANG X F, CAO G M, DIAO X L, et al. Vimentin protein in situ expression predicts less tumor metastasis and overall better survival of endometrial carcinoma[J]. Dis Markers, 2022, 2022: 5240046.
[10] 王媛秋, 曹琳彦, 郑飞云. 术前外周血中平均血小板体积与血小板计数的比率对上皮性卵巢癌患者预后影响的研究[J]. 实用妇产科杂志, 2021, 37(9): 673-677.
[11] XIAO Z H, JIA Y, JIANG W P, et al. FOXM1: a potential indicator to predict lymphatic metastatic recurrence in stage IIA esophageal squamous cell carcinoma[J]. Thorac Cancer, 2018, 9(8): 997-1004.
[12] PARK Y L, KIM H P, OCK C Y, et al. EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer[J]. Oncogene, 2022, 41(14): 2026-2038.
[13] 黎超莲, 邹嘉雯, 李荣威, 等. HOXA5、E-cadherin、β-catenin在卵巢癌组织中的表达[J]. 安徽医科大学学报, 2019, 54(7): 1092-1096.
[14] 赵平凡, 吕艳华, 赵田, 等. miR-302a靶向E2F1抑制胃癌BGC-823细胞EMT并降低细胞侵袭和迁移能力的实验研究[J]. 胃肠病学和肝病学杂志, 2020, 29(2): 131-135.
[15] MENG F D, WEI J C, QU K, et al. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(1): 196-213.
[16] KYUNO T, KOHNO T, KONNO T, et al. Glucose-dependent FOXM1 promotes epithelial-to-mesenchymal transition via cellular metabolism and targeting snail in human pancreatic cancer[J]. Pancreas, 2020, 49(2): 273-280.
[17] BALLI D, USTIYAN V, ZHANG Y F, et al. Foxm1 transcription factor is required for lung fibrosis and epithelial-to-mesenchymal transition[J]. EMBO J, 2013, 32(2): 231-244.
[18] KONG F F, QU Z Q, YUAN H H, et al. Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer[J]. Oncol Rep, 2014, 31(6): 2660-2668.

Expression and clinical significance of FoxM1 in epithelial ovarian cancers

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Recommended Articles

Metrics

Comments

[1]	TAN Jianhua, LAI Yaozhen, TANG Lihua, ZHOU Li. Efficacy and prognostic values of two treatments for advanced epithelial ovarian cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 131-138.
[2]	LI Youmei, ZHANG Siyi, ZHAO Lianmei, SHAN Baoen, ZHANG Chao. Expressions of LIN28A,E-cadherin and vimentin in invasive breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(4): 304-308,312.
[3]	MO Qianzhen, SHEN Jiaxin, CHEN Minna, LIU Jing. Meta-analysis of the relationship between E-cadherin and clinicopathological indicators in patients with breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(4): 284-291.
[4]	CAI Xiaoman, CHEN Suzuan, YU Jing, LIU Zhaohui, WU Ruinuan, TANG Shengxin, GUO Guanghua. The significance and expression of caveolin-1 and E-cadherin in esophageal carcinoma cell line TE1 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(3): 227-230.
[5]	JING Shaowu, XU Qing, WANG Jun, YANG Congrong, LI Guangqing, ZHAO Zhen, ZHAO Zhijun, JING Shanghua. Relationship between aberrant expression of E-cadherin and clinicopathological characteristics of nasopharyngeal carcinoma: a Meta-analysis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(2): 97-102,106.
[6]	ZHENG Haixia, CUI Yongyan, SHEN Donglan, PENG An, HE Yanling. Influences of nm23-H1 gene transfection on expressions of adhesion molecules in lung cancer cell line L9981 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2015, 27(2): 134-136,141.
[7]	. Expressions of MMP-2 and E-cadherin in esophageal mucosal lesion Expressions of MMP-2 and E-cadherin in esophageal mucosal lesion [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2014, 26(4): 288-297.
[8]	QIU Zhi-qun, SHU Wei-qun, CHEN Ji-an, LUO Jiao-hua, YANG Lan, ZHENG You-ke, CAO Jia. Combined Effect of Di-n-butyl Phthalate and Benzo(a)pyrene on Vimentin and α-tubulin in Rat Sertoli Cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2009, 21(3): 165-168.